A total of 332 patients entered the study and 277 patients were randomised and treated, 137 with FP250µg twice daily via Diskus TM inhaler and 140 with budesonide 600µg twice daily via Turbuhaler TM.
Budesonide-formoterol inhaler was as effective as fluticasone-salmeterol in reducing the incidence of moderate-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback